154 related articles for article (PubMed ID: 15363862)
21. Dormant hypermethylated tumour suppressor genes: questions and answers.
Esteller M
J Pathol; 2005 Jan; 205(2):172-80. PubMed ID: 15643671
[TBL] [Abstract][Full Text] [Related]
22. Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells.
Song JZ; Stirzaker C; Harrison J; Melki JR; Clark SJ
Oncogene; 2002 Feb; 21(7):1048-61. PubMed ID: 11850822
[TBL] [Abstract][Full Text] [Related]
23. Methylation of the CD44 metastasis suppressor gene in human prostate cancer.
Lou W; Krill D; Dhir R; Becich MJ; Dong JT; Frierson HF; Isaacs WB; Isaacs JT; Gao AC
Cancer Res; 1999 May; 59(10):2329-31. PubMed ID: 10344738
[TBL] [Abstract][Full Text] [Related]
24. DNA methylation in promoter region as biomarkers in prostate cancer.
Yang M; Park JY
Methods Mol Biol; 2012; 863():67-109. PubMed ID: 22359288
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.
Bastian PJ; Ellinger J; Wellmann A; Wernert N; Heukamp LC; Müller SC; von Ruecker A
Clin Cancer Res; 2005 Jun; 11(11):4097-106. PubMed ID: 15930345
[TBL] [Abstract][Full Text] [Related]
26. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation.
Kondo Y; Shen L; Cheng AS; Ahmed S; Boumber Y; Charo C; Yamochi T; Urano T; Furukawa K; Kwabi-Addo B; Gold DL; Sekido Y; Huang TH; Issa JP
Nat Genet; 2008 Jun; 40(6):741-50. PubMed ID: 18488029
[TBL] [Abstract][Full Text] [Related]
27. Predicting aberrant CpG island methylation.
Feltus FA; Lee EK; Costello JF; Plass C; Vertino PM
Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12253-8. PubMed ID: 14519846
[TBL] [Abstract][Full Text] [Related]
28. [Epigenetics of prostate cancer].
Yi XM; Zhou WQ
Zhonghua Nan Ke Xue; 2010 Jul; 16(7):635-41. PubMed ID: 20873600
[TBL] [Abstract][Full Text] [Related]
29. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
Bastian PJ; Palapattu GS; Lin X; Yegnasubramanian S; Mangold LA; Trock B; Eisenberger MA; Partin AW; Nelson WG
Clin Cancer Res; 2005 Jun; 11(11):4037-43. PubMed ID: 15930338
[TBL] [Abstract][Full Text] [Related]
30. Methylation mediated silencing of TMS1/ASC gene in prostate cancer.
Das PM; Ramachandran K; Vanwert J; Ferdinand L; Gopisetty G; Reis IM; Singal R
Mol Cancer; 2006 Jul; 5():28. PubMed ID: 16848908
[TBL] [Abstract][Full Text] [Related]
31. The role of DNA hypermethylation in human neoplasia.
Toyota M; Issa JP
Electrophoresis; 2000 Jan; 21(2):329-33. PubMed ID: 10675010
[TBL] [Abstract][Full Text] [Related]
32. Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.
Kristensen H; Haldrup C; Strand S; Mundbjerg K; Mortensen MM; Thorsen K; Ostenfeld MS; Wild PJ; Arsov C; Goering W; Visakorpi T; Egevad L; Lindberg J; Grönberg H; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Clin Cancer Res; 2014 Apr; 20(8):2169-81. PubMed ID: 24737792
[TBL] [Abstract][Full Text] [Related]
33. DNA methylation and cancer.
Momparler RL; Bovenzi V
J Cell Physiol; 2000 May; 183(2):145-54. PubMed ID: 10737890
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of N-myc downstream regulated gene 1 caused by the methylation of CpG islands of NDRG1 promoter promotes proliferation and invasion of prostate cancer cells.
Li Y; Pan P; Qiao P; Liu R
Int J Oncol; 2015 Sep; 47(3):1001-8. PubMed ID: 26202882
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic inactivation of the dioxin-responsive cytochrome P4501A1 gene in human prostate cancer.
Okino ST; Pookot D; Li LC; Zhao H; Urakami S; Shiina H; Igawa M; Dahiya R
Cancer Res; 2006 Aug; 66(15):7420-8. PubMed ID: 16885337
[TBL] [Abstract][Full Text] [Related]
36. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer.
Enokida H; Shiina H; Igawa M; Ogishima T; Kawakami T; Bassett WW; Anast JW; Li LC; Urakami S; Terashima M; Verma M; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Cancer Res; 2004 Sep; 64(17):5956-62. PubMed ID: 15342374
[TBL] [Abstract][Full Text] [Related]
37. Functional epigenomics identifies genes frequently silenced in prostate cancer.
Lodygin D; Epanchintsev A; Menssen A; Diebold J; Hermeking H
Cancer Res; 2005 May; 65(10):4218-27. PubMed ID: 15899813
[TBL] [Abstract][Full Text] [Related]
38. Methylated genes as potential biomarkers in prostate cancer.
Phé V; Cussenot O; Rouprêt M
BJU Int; 2010 May; 105(10):1364-70. PubMed ID: 20067451
[TBL] [Abstract][Full Text] [Related]
39. [DNA methylation and prostate cancer].
Zhou SG; Sun YH; Gao JP
Zhonghua Nan Ke Xue; 2007 Dec; 13(12):1108-12. PubMed ID: 18284062
[TBL] [Abstract][Full Text] [Related]
40. Altered regulation of DNA ligase IV activity by aberrant promoter DNA methylation and gene amplification in colorectal cancer.
Kuhmann C; Li C; Kloor M; Salou M; Weigel C; Schmidt CR; Ng LW; Tsui WW; Leung SY; Yuen ST; Becker N; Weichenhan D; Plass C; Schmezer P; Chan TL; Popanda O
Hum Mol Genet; 2014 Apr; 23(8):2043-54. PubMed ID: 24282031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
